FDA panel backs menopausal hormone therapy
Why it matters: The meeting highlighted an area of particular interest for FDA commissioner Marty Makary, who cited warnings about hormone therapy in his book "Blind Spots" as an example of medical groupthink that caused unnecessary harm.
Driving the news: The 12-member panel of mostly like-minded physicians focused on the impacts of the warnings — the strongest the FDA can give a prescription drug — in stalling uptake of the therapies.
While the panel didn't take a vote and has no authority to change policy, the sentiment expressed could open the door to a labeling change.
The big picture: There's been increased attention to the once-taboo topic of menopause in recent years.
Many providers stopped prescribing hormone therapy following research from the Women's Health Initiative in 2002 that found it increased a woman's risk of heart disease and breast cancer.
Since the following year, all hormone therapies for menopause have carried warnings citing increased risk of cardiovascular events, some cancers and dementia.
In recent years, more women's health experts called for that research to be put into context. They've argued that risks were overstated and the data was weighted toward women 60 and older while the average age of a menopausal woman is 51.
The original study's authors wrote in JAMA last year that the benefits of hormone therapy outweigh the risks in many menopausal women.
Between the lines: During the meeting Thursday, several experts highlighted benefits women with menopause could reap from estrogen treatments when it came to reducing their risk of fatal heart attacks or bone fractures.
In particular, they homed in on the differences in risk presented by transdermal vaginal estrogen creams and gels versus pills.
The Menopause Society and American College of Obstetricians and Gynecologists have both called for the removal of the black box warning on vaginal estrogen.
"Vaginal or local estrogen is categorically safe for all women, period. Because it does not travel systemically there, again, are no increased risks of heart attacks, clots or strokes, and the black box warning is wrong" said Heather Hirsch, an internist who served on the panel.
She called systemic hormone therapy warnings "broad and poorly defined."
Yes, but: Thursday's meeting still irked critics who said the panel is stacked with experts to support a predetermined conclusion and could influence FDA policy without public comment.
The panel itself had several financial incentives to support the wider adoption of hormone therapy, with several providers who consult for pharmaceutical companies or who made money from prescribing the medications, the New York Times reported.
"The claim that the FDA's expert advisory process is 'one-sided' or politically driven is insulting to the independent scientists, clinicians, and researchers who dedicate their expertise to these panels," an HHS spokesperson said in a statement.
The panelists are largely relying on observational studies, which can put undue weight on the benefits of the therapy, said Adriane Fugh-Berman, a Georgetown University professor of pharmacology who wrote a critique of the panel Thursday in American Family Physician.
"It is a reasonable treatment for severe menopausal symptoms ... as long as women are actually informed of possible harms," she told Axios.
The bottom line: While use of hormone therapy for menopause has been limited by the black box warnings, its popularity is growing, driven by women's health providers and businesses promoting its use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
5 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
Wall Street Journal
7 hours ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
